• Marinus scores in Phase III genetic epilepsy drug study, wins BARDA contract for IV formulation

    11 days ago - By MedCity News

    The company announced a contract with BARDA to develop intravenous ganaxolone for a seizure disorder that can result from exposure to nerve agents, in addition to announcing successful results from its Phase III trial of the oral version of the drug in a CDKL5 deficiency disorder, or CDD.
    Read more ...